PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades.

Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.

The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.

By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

For further information, please visit:
http://www.predictad.eu

Project co-ordinator:
Valtion teknillinen tutkimuskeskus VTT

Partners:

  • Nexstim Oy
  • Imperial College of Science, Technology and Medicine
  • Rigshospitalet
  • Kuopion yliopisto
  • Università degli Studi di Milano
  • GE Healthcare Ltd.
  • Uppsala universitet

Timetable: from 06/2008 – to 05/2011

Total cost: € 3.981.565

EC funding: € 2.891.526

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

NHS and Patients to Benefit from New Par…

IMS MAXIMS and Secure Exchange Solutions have announced a partnership to offer mobile, secure and cost-effective provider-to-provider and provider-to-patient communications to NHS organisations, GP practices and patients.

International Master's in Digital Health

The Master of Science (M.Sc.) in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule...

Digital Medicine: The Opportunities and …

9 - 11 April 2019, Berlin, Germany. Be it preventive healthcare for dementia using intuitive apps, anonymous hospital hygiene inspections using IoT sensors, or VR applications that let hemiplegic patients live...

Highland Marketing Forms Alliance with E…

An alliance between Highland Marketing and Experiential HealthTech will be announced at this year's Digital Health Rewired, with both companies exhibiting from stand B14. Highland Marketing is a full-service marketing...

Google Research Shows How AI can Make Op…

As artificial intelligence continues to evolve, diagnosing disease faster and potentially with greater accuracy than physicians, some have suggested that technology may soon replace tasks that physicians currently perform. But...

Virtual Reality could be Used to Treat A…

Playing games in virtual reality (VR) could be a key tool in treating people with neurological disorders such as autism, schizophrenia and Parkinson's disease. The technology, according to a recent...

Open Call SC1-HCC-02-2019: Support for t…

In the past years several open service platforms for Active and Healthy Ageing domains have been developed, originating from the medical, independent living, and IoT domain. These platforms aim at...

Have an Innovative Digital Health Soluti…

G4A Partnerships are a great opportunity to get your solution in front of Bayer executives and decision makers. All the applications will be reviewed by key stakeholders who have global...

The Moore Blatch Silicon Cup Opens for E…

This year's Moore Blatch Silicon Cup has been launched and is now open for IT companies to enter. The event takes place over 26 - 27 September on the Isle...

MEDICA 2019: Clear Focus on Future Topic…

18 - 21 November 2019, Düsseldorf, Germany. As a result of the final phase of exhibitor registrations for the world’s leading medical trade fare MEDICA 2019 in Düsseldorf, one thing is...

Artificial Intelligence Sheds New Light …

What happens inside a cell when it is activated, changing, or responding to variations in its environment? Researchers from the VIB-UGent Center for Inflammation Research have developed a map of...